Actinium Pharmaceuticals inc (NYSE:ATNM) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Actinium Pharmaceuticals inc (NYSE:ATNM) gained 9 Percent and closed its previous trading session at $0.73. The stock traded with the average Volume of 1.42 Million at the end of last session.
Actinium Pharmaceuticals inc (NYSE:ATNM) has the Market Capitalization of 80.43 Million. The Stock has its 52-week High of $1.100 and 52-Week Low of $0.330 and it touched its 52-week high on 07/17/17 and 52-Week Low on 04/24/18
The company reported its last earnings Actual EPS of $-0.07/share. While, the analyst predicted that the company could provide an EPS of $-0.06/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -16.7 Percent.
Sell side analysts plays vital role in buying and selling a stock where 4 analysts rated Actinium Pharmaceuticals inc (NYSE:ATNM) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 18.88% where SMA50 and SMA200 are 53.99% and 31.33% respectively.
The company shows its Return on Assets (ROA) value of -122.5%. The Return on Equity (ROE) value stands at -159.1%.
Actinium Pharmaceuticals inc (NYSE:ATNM) currently has a Weekly Volatility of 9.17% percent while its Monthly Volatility is at 11.60% percent. While talking about Performance of the Stock, Actinium Pharmaceuticals inc currently has a Weekly performance of 17.78%, monthly performance percentage is 61.53 percent, Quarterly performance is 92.54 percent, 6 months performance shows a percent value of 3.09% and Yearly Performance is -29.12 percent.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York.